Taficita
Dosage form
Tablets for oral administration. Each tablet contains 200 mg of emtricitabine and 25 mg of tenofovir alafenamide
Please note that the appearance of the packaging may vary depending on the manufacturer and region of sale.
Active ingredient
Emtricitabine and tenofovir alafenamide.
Dosage
One tablet (200 mg emtricitabine and 25 mg tenofovir alafenamide) once daily.
Indications for Use
- Treatment of HIV-1 infection in adults and adolescents aged 12 years and older weighing at least 35 kg as part of combination antiretroviral therapy.
Contraindications
- Hypersensitivity to emtricitabine, tenofovir alafenamide, or any excipients of the product.
- Severe renal impairment (creatinine clearance <30 mL/min).
- Concurrent use with other medications containing tenofovir or emtricitabine.
Adverse Effects
Common:
- Nausea, vomiting, diarrhea, headache, dizziness, rash, fatigue.
Rare:
- Lactic acidosis, hepatomegaly, renal impairment, osteomalacia.
Very rare:
- Pancreatitis, rhabdomyolysis, allergic reactions.
Recommendations for Use
Administration:
- Take orally, preferably with food, once daily.
Special Instructions:
- Before initiating therapy, conduct HIV testing and assess renal and hepatic function.
- Regular monitoring of renal function and viral load is essential during treatment.
Drug Interactions:
- Avoid concurrent use with nephrotoxic drugs and other antiretroviral agents containing tenofovir or emtricitabine.
Before starting therapy, consult a healthcare provider and review the complete prescribing information.
